Altesa Biosciences, a clinical-stage biopharmaceutical company focused on the development of novel antiviral drugs, has constituted a new scientific advisory board comprising leading academic and industry leaders in pulmonology, infectious diseases, virology, paediatrics and drug development. The team, which possesses the experience and vision to assist in advancing Altesa’s first clinical-stage drug, vapendavir, into advanced clinical trials to improve the lives of patients living with COPD, will assist in accelerating Altesa’s pipeline of other potentially life-saving drugs and also help advance novel antiviral drugs. 

Source: businesswire